Provided by Tiger Trade Technology Pte. Ltd.

SciSparc Ltd.

5.85
+0.18023.18%
Volume:45.12K
Turnover:250.62K
Market Cap:3.40M
PE:-0.06
High:6.00
Open:5.80
Low:5.41
Close:5.67
52wk High:80.10
52wk Low:2.98
Shares:581.00K
Float Shares:561.10K
Volume Ratio:2.05
T/O Rate:8.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-98.0714
EPS(LYR):-98.0714
ROE:-178.39%
ROA:-60.68%
PB:0.80
PE(LYR):-0.06

Loading ...

SciSparc Subsidiary NeuroThera Pursues FDA Orphan Drug Designation for Tourette Drug SCI-110

Reuters
·
Yesterday

Scisparc: Subsidiary Neurothera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm Rk Strategies

THOMSON REUTERS
·
Yesterday

SciSparc subsidiary provides update on SCI-210 trial enrollment

TIPRANKS
·
Sep 01

SciSparc Subsidiary NeuroThera Labs Enrolls 26 Children in SCI-210 Autism Trial

Reuters
·
Sep 01

Scisparc: Subsidiary Neurothera Labs Achieves Significant Enrollment Momentum in Sci‑210 Autism Clinical Trial

THOMSON REUTERS
·
Sep 01

Psychedelic: SciSparc, Clearmind publish patent application for PTSD treatment

TIPRANKS
·
Aug 28

SciSparc Adds AI Expert Carmel Domshlak to Scientific Advisory Board

Reuters
·
Aug 26

SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination

TIPRANKS
·
Aug 24

Scisparc: Neurothera-Clearmind Collaboration Advances Mdma-N-Acylethanolamines Ip for the Treatment of Ptsd Amid Rising U.S. Federal Support for Psychedelic Innovation

THOMSON REUTERS
·
Aug 24

Scisparc Posts Audited 2025 Net Loss of USD 12.56 Million

Reuters
·
Aug 19

Scisparc: Subsidiary Neurothera Labs Completes C$5.4 Million Financing with Scisparc’s Stake Valued at Approximately C$30 Million

THOMSON REUTERS
·
Aug 18

NeuroThera Labs Raises C$ 2.7 Million in First Tranche of Non-Brokered Private Placement at C$ 0.12 Per Unit

Reuters
·
Aug 13

SciSparc Unit NeuroThera Labs Wins Japanese Patent for Paracetamol Combination Therapy

Reuters
·
Aug 12

Scisparc’s Subsidiary Neurothera Labs Granted Japanese Patent for Its Proprietary, Innovative Therapeutic Combination

THOMSON REUTERS
·
Aug 12

SciSparc Subsidiary NeuroThera Launches Phase IIb Tourette Trial Site at Yale Child Study Center

Reuters
·
Aug 05

Scisparc: Subsidiary Neurothera Labs Launches Phase Iib Clinical Trial at Yale Child Study Center for First-of-Its-Kind Treatment for Tourette Syndrome

THOMSON REUTERS
·
Aug 05

SciSparc Subsidiary NeuroThera Labs’ Quantum Platform Completes End-to-end Hybrid Workflow for Clinical Data Analytics

Reuters
·
Jul 31

NASDAQ Trade Halt Volatility Trading Pause at 10:22 Am

Reuters
·
Jul 29

Scisparc Ltd trading halted, volatility trading pause

TIPRANKS
·
Jul 29

SciSparc Targets Agentic AI Market as New Growth Strategy

Reuters
·
Jul 29